Senior Thought Leader Liaison, Neurology Rare Disease (Remote)

Otsuka America Pharmaceutical Inc.; Trenton (NJ); Remote; USD 169,000 - 253,000; Full time

Benefits offered by this job

Medical benefits

401(k) match

Paid time off

Job summary

Otsuka America Pharmaceutical, Inc. seeks an Associate Director, Thought Leader Liaison (TLL) in Neurology Rare Disease. This senior, field‑based role blends scientific fluency with thought‑leader engagement to shape regional plans and education strategies.

Responsibilities include coordinating with MSLs, developing nonpromotional disease education pre‑approval, and guiding launch‑readiness efforts post‑approval while maintaining compliant practices.

Qualifications

• Eight+ years of relevant biopharmaceutical field experience.
• Experience in thought‑leader engagement or strategic field roles.
• Strong clinical and scientific fluency for discussions with senior clinicians.
• Ability to operate independently in a field role without an established franchise.

Responsibilities

• Develop and execute a regional plan aligned with national launch priorities.
• Map thought leaders, institutions, and referral relationships within the region.
• Collaborate with MSLs and cross‑functional teams to support education and market development.
• Lead engagement strategies for congresses, advisory boards, and partnerships.

Skills

Leadership

Strategic thinking

Relationship building

Executive presence

Communication skills

Project coordination

Cross-functional collaboration

Field-based engagement

Education

Bachelor’s degree

Advanced clinical/scientific/public health or business degree

Job description

Otsuka America Pharmaceutical, Inc. seeks an Associate Director, Thought Leader Liaison (TLL) in Neurology Rare Disease. This senior, field‑based role blends scientific fluency with thought‑leader engagement to shape regional plans and education strategies.

Responsibilities include coordinating with MSLs, developing nonpromotional disease education pre‑approval, and guiding launch‑readiness efforts post‑approval while maintaining compliant practices.